These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

943 related items for PubMed ID: 21949042

  • 1. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.
    Carr S, Allison KJ, Van De Velde LA, Zhang K, English EY, Iverson A, Daw NC, Howard SC, Navid F, Rodriguez-Galindo C, Yang J, Adderson EE, McCullers JA, Flynn PM.
    J Infect Dis; 2011 Nov 15; 204(10):1475-82. PubMed ID: 21949042
    [Abstract] [Full Text] [Related]

  • 2. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
    Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE.
    Vaccine; 2008 Sep 08; 26(38):4940-6. PubMed ID: 18662737
    [Abstract] [Full Text] [Related]

  • 3. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
    Mallory RM, Yi T, Ambrose CS.
    Vaccine; 2011 Jun 10; 29(26):4322-7. PubMed ID: 21513761
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B, CAIV-T Asthma Study Group.
    Pediatr Infect Dis J; 2006 Oct 10; 25(10):860-9. PubMed ID: 17006278
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.
    King JC, Treanor J, Fast PE, Wolff M, Yan L, Iacuzio D, Readmond B, O'Brien D, Mallon K, Highsmith WE, Lambert JS, Belshe RB.
    J Infect Dis; 2000 Feb 10; 181(2):725-8. PubMed ID: 10669363
    [Abstract] [Full Text] [Related]

  • 6. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
    Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J.
    Vaccine; 2011 Nov 21; 29(50):9391-7. PubMed ID: 21983154
    [Abstract] [Full Text] [Related]

  • 7. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM, Li YQ, Zheng TZ, Jia YP, Li F, Han TW, Qiao RX, Zhang BH.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul 21; 24(7):570-3. PubMed ID: 12975010
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
    Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N.
    Pediatr Infect Dis J; 2012 May 21; 31(5):494-500. PubMed ID: 22301476
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children.
    Block SL, Falloon J, Hirschfield JA, Krilov LR, Dubovsky F, Yi T, Belshe RB.
    Pediatr Infect Dis J; 2012 Jul 21; 31(7):745-51. PubMed ID: 22466322
    [Abstract] [Full Text] [Related]

  • 10. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep 21; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
    Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.
    BMC Infect Dis; 2013 Jul 24; 13():343. PubMed ID: 23883186
    [Abstract] [Full Text] [Related]

  • 12. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.
    King JC, Fast PE, Zangwill KM, Weinberg GA, Wolff M, Yan L, Newman F, Belshe RB, Kovacs A, Deville JG, Jelonek M, HIV Influenza Study Group.
    Pediatr Infect Dis J; 2001 Dec 24; 20(12):1124-31. PubMed ID: 11740317
    [Abstract] [Full Text] [Related]

  • 13. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T, Forstén A, Arora A, Tsai T, Clemens R.
    Hum Vaccin Immunother; 2015 Dec 24; 11(8):2102-12. PubMed ID: 26091244
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
    Rodriguez Weber MA, Claeys C, Aranza Doniz C, Feng Y, Innis BL, Jain VK, Peeters M.
    Pediatr Infect Dis J; 2014 Dec 24; 33(12):1262-9. PubMed ID: 25386965
    [Abstract] [Full Text] [Related]

  • 15. Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer.
    Halasa N, Englund JA, Nachman S, Weinberg GA, Huber VC, Allison K, Dubovsky F, Yi T, McCullers JA, Flynn PM.
    Vaccine; 2011 May 31; 29(24):4110-5. PubMed ID: 21496468
    [Abstract] [Full Text] [Related]

  • 16. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
    Englund JA, Walter E, Black S, Blatter M, Nyberg J, Ruben FL, Decker MD, GRC28 Study Team.
    Pediatr Infect Dis J; 2010 Feb 31; 29(2):105-10. PubMed ID: 19934787
    [Abstract] [Full Text] [Related]

  • 17. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.
    Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ.
    J Infect Dis; 2009 Sep 15; 200(6):849-57. PubMed ID: 19673652
    [Abstract] [Full Text] [Related]

  • 18. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kühr J, Bujnowski T, Desgrandchamps D, Cheng SM, Skinner J, Gruber WC, Forrest BD, CAIV-T Study Group.
    Pediatr Infect Dis J; 2006 Oct 15; 25(10):870-9. PubMed ID: 17006279
    [Abstract] [Full Text] [Related]

  • 19. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older.
    Forrest BD, Steele AD, Hiemstra L, Rappaport R, Ambrose CS, Gruber WC.
    Vaccine; 2011 May 09; 29(20):3633-9. PubMed ID: 21440036
    [Abstract] [Full Text] [Related]

  • 20. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
    Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD.
    Vaccine; 2013 Jan 21; 31(5):770-6. PubMed ID: 23228813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.